Research Ethics

The centre for Applied Ethics was created in April 2014 as part of a broad restructuring of ethics services at the MUHC.  The 9 Research Ethics Boards (REBs), as well as research ethics, support services have been part of this exercise.   Changes to the REB structure come into effect April 1, 2015.  These will not affect the general principles of how research involving humans is approved.  However, these changes aim at increasing efficiency while maintaining high-quality review of research.

  • There is one MUHC REB and 5 specialised panels
  • The 5 specialised panels will conduct both Science and Ethics review and will meet twice a month on average;
  • Submission deadlines are abolished;
  • completeness, 
  • minimal quality of documents submitted and 
  • assess level of risk and initiate delegated review of minimal risk studies (instead of full board reviews).
  • The CAE staff will conduct pre-reviews of all studies to ensure 

The MUHC currently has a single REB with 5 specialized panels :

  • PED
  • NEUPSY
  • CT1 (Oncology)
  • CT2
  • CTGQ

5 Panels of the MUHC-REB

Pediatrics (PED):
  • All projects involving minors
Clinical Trials 1 (CT1):
  • Oncology
  • Radiation-oncology
  • ObGyn
  • Urology
  • Palliative care research associated to oncology
Cells, tissues, genetics & qualitative research (CTGQ):
  • Genetics
  • Biobanking and registries
  • Research on cells and tissues
  • Experimental  cell therapies
  • Pathology
  • Regenerative medicine
  • Epidemiology 
  • Qualitative research
Neurosciences-Psychiatry (NEUPSY):
All projects in:
  • Neuroscience
  • Psychiatry
  • Psychology
Clinical Trials 2 (CT2):
  • Surgery
  • Cardiology
  • Orthopaedics
  • Endocrinology
  • Anesthesiology
  • Gastroenterology
  • Urology
  • Devices
  • Infectious diseases
  • Chronic illness
  • Respiratory and
  • Transplant

MUHC REB Chair: Marie Hirtle

MUHC - Personne Mandatée: Marie Hirtle

Panels

Co-chairs:

REB Coordination 

PEDS

Vincent Lajoie 

Elizabeth Craven

NEUPSY

Marie-Josée Brouillette, Judith Marcoux

Kathy Laperriere

CT1

Vincent Lajoie

Kathy Laperriere

CT2 

Bertrand Lebouché, Thomas Maniatis, Sonya Page

Sheldon Levy 

CTGQ

Marie Hirtle James Ellasus

Schedule of REB FULLBOARD meetings

For the schedule of REB full board meetings, please see in Nagano. Note that studies that are more than minimal risk are reviewed at the fullboard.

Please enter your study in Nagano as soon as possible to initiate the review process.

See also: